RA
CCCC icon

Royce & Associates’s C4 Therapeutics CCCC Stock Holding History

Royce & Associates’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,604
Closed -$193K – 880
2024
Q1 		$193K Sell
23,604
-18,950
-45% -$147K ﹤0.01% 835
2023
Q4 		$240K Buy
+42,554
New +$97K ﹤0.01% 833

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Royce & Associates's CCCC Position: Q2 2024 in Review

Royce & Associates sold out of C4 Therapeutics (CCCC) in Q2 2024, closing a stake of 23,604 shares — an estimated $193K sold.

Royce & Associates first reported a position in CCCC in Q4 2023 and held it in 2 quarters. The position peaked at $240K in Q4 2023. 115 funds tracked by Wall St. Rank hold CCCC as of Q2 2024.

  • Royce & Associates reported no remaining C4 Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Royce & Associates sold 23,604 C4 Therapeutics shares in Q2 2024, an estimated $193K.
  • Royce & Associates first reported a position in C4 Therapeutics in Q4 2023 and held it in 2 quarters.
  • Royce & Associates's C4 Therapeutics position peaked at $240K in Q4 2023.
  • 115 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2024.

Based on Royce & Associates's 13F filing for Q2 2024, filed 13 Aug 2024.